NCT02711553 2025-08-03
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT02791334 2024-09-27
PACT
Eli Lilly and Company
Phase 1 Completed
NCT02920996 2024-04-11
Merestinib In Non-Small Cell Lung Cancer And Solid Tumors
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03292536 2021-01-08
Merestinib on Bone Metastases in Subjects With Breast Cancer
University of Utah
Phase 1 Terminated
NCT03027284 2020-05-19
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02745769 2019-03-05
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Eli Lilly and Company
Phase 1 Completed
NCT01285037 2018-02-20
A Study of LY2801653 in Advanced Cancer
Eli Lilly and Company
Phase 1 Completed